Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Lemann

Showing results (41-50 of 43) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 43 results.
Arthritis and Rheumatism|July 1, 2009
Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registryF Tubach, D Salmon, P Ravaud, et al.
Gastroenterologie Clinique Et Biologique|February 15, 2002
[Infliximab therapy for Crohn's disease anoperineal lesions]A Ouraghi, S Nieuviarts, J L Mougenel, et al.
Alimentary Pharmacology & Therapeutics|January 3, 2013
Development and validation of a patient-reported disability measurement tool for patients with inflammatory bowel diseaseP B Allen, M A Kamm, L Peyrin-Biroulet, et al.
Pageof 5

Showing results (41-50 of 43) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 43 results.
Arthritis and Rheumatism|July 1, 2009
Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registryF Tubach, D Salmon, P Ravaud, et al.
Gastroenterologie Clinique Et Biologique|February 15, 2002
[Infliximab therapy for Crohn's disease anoperineal lesions]A Ouraghi, S Nieuviarts, J L Mougenel, et al.
Alimentary Pharmacology & Therapeutics|January 3, 2013
Development and validation of a patient-reported disability measurement tool for patients with inflammatory bowel diseaseP B Allen, M A Kamm, L Peyrin-Biroulet, et al.
Pageof 5